Compound: erythromycin
SMILES: O=C1O[C@@H]([C@@](O)([C@H](O)[C@H](C(=O)[C@H](C)C[C@]([C@@H]([C@H]([C@@H]([C@H]1C)O[C@@H]2O[C@H]([C@H](O)[C@@](C2)(OC)C)C)C)O[C@@H]3O[C@@H](C[C@@H]([C@H]3O)N(C)C)C)(O)C)C)C)CC
InChIKey: ULGZDMOVFRHVEP-RWJQBGPGSA-N
Synonyms: erythromycin, 114-07-8, Erythromycin A, Abomacetin, Emgel, Erymax, Ilotycin, Eritromicina, Erythromycine, Erythromycinum, Robimycin, Eryderm, Erythromycin base, Erycette, Erygel, Sansac, E-Mycin, Erythro-Statin, Erythra-Derm, Akne-Mycin, ERYC, E-Glades, Ery-Tab, E-Base, Stiemycin, R-P Mycin, Eryc Sprinkles, E-Solve 2, Erythromast 36, T-Stat, Torlamicina, C-Solve-2, Erythrogran, Eryc 125, erythromycin-A, Erythroguent, Dotycin, Oftalmolosa Cusi Eritromicina, Staticin, Retcin, DTXSID4022991, J01FA01, NSC-55929, PCE (ERYTHROMYCIN), 63937KV33D, DTXCID102991, CHEBI:42355, NSC55929, (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione, 7540-22-9, Kerymax, Spotex, Erymax sprinkle, Aknemycin plus, TStat, Eryacne 2, Eryacne 4, Gallimycin-36, T Stat, (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl)oxy)-14-ethyl-7,12,13-trihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy)-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione, (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl)oxy-14-ethyl-7,12,13-trihydroxy-4-((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione, (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-((2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl)oxy-14-ethyl-7,12,13-trihydroxy-4-((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione, (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione, (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione, Erythro 200, Lactate, Erythromycin, Rommix 250 ec, Rommix 500 ec, Phosphate, Erythromycin, RefChem:6427, Erythro-100 Injection, API E.M. Erythromycin, Erythromycin Base Filmtab, Erythro-36, Erythro-Dry, API E.M ERYTHROMYCIN, CHEBI:48923, erythromycin topical solution 2%, Gallimycin Injection, Gallimycin-100, (2R,3S,4S,5R,6R,8R,10R,11R,12S,13R)-5-(3,4,6-Trideoxy-3-dimethylamino-beta-D-xylo-hexopyranosyloxy)-3-(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyloxy)-6,11,12-trihydroxy-2,4,6,8,10,12-hexamethyl-9-oxopentadecan-13-olide, 204-040-1, 616-217-4, 3''-O-Demethylerythromycin, RP-Mycin, Eryacne, Erythrocin, Pantomicina, MFCD00084654, A/T/S, erythro, Ermycin, Erycen, Aknin, Theramycin Z, Ak-Mycin, Erytab, Inderm, Benzamycin, CHEMBL532, Dumotrycin, Mephamycin, Wemid, (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-ethyl-7,12,13-trihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione, Erythromycin C-13, Endoeritrin, Eritomicina, Erythroderm, Erytrociclin, Pharyngocin, Proterytrin, Acneryne, Acnesol, Aknemycin, C37H67NO13, Derimer, Deripil, Erisone, Eryacnen, Erydermer, Eryhexal, Erysafe, Iloticina, Latotryd, Lederpax, Mercina, Oftamolets, Pantoderm, Pantodrin, Romycin, Stiemicyn, Tiprocin, Emuvin, Emycin, Erecin, Erymed, Erytop, AustriaS, Eros, Ery-maxin, Erythro-Teva, Sans-acne, Erimycin-T, Ery-Diolan, Inderm Gel, Del-Mycin, Aknederm Ery Gel, Udima Ery Gel, cyclotetradecane-2,10-dione, Emu-Ve, 8HPH7ND0LN, Skid Gel E, (3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)oxacyclotetradecane-2,10-dione, Akne Cordes Losung, ERY, Ilosone (estolate), Ilotycin T.S., E-Mycin (base), Ery-Tab (base), Emu-V, Ery-B, E-Base (base), ERYC (base), N-Methylerythromycin A, PCE Dispertab (base), Eryc-125, Eryc-250, Eritromicina [INN-Spanish], Erythromycine [INN-French], Erythromycinum [INN-Latin], Erythromycin, labeled with carbon-13, Staticin (TN), (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione, Akne-mycin (TN), Erygel (TN), Eryc (TN), T-stat (TN), Pce (TN), SR-05000001618, Sentry AQ mardel maracyn, Erythromycin & VRC3375, erthromycin, trahydro-2H-pyran-2-yl)oxy)-3,5,7,9,11,13-hexamethyloxa, CCRIS 9078, Erythromycin RS, 82343-12-2, UNII-63937KV33D, HSDB 3074, NCGC00094670-01, Erythromycin [USP:INN:BAN:JAN], (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-ethyl-7,12,13-trihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethylte, (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione, CAS-114-07-8, Prestwick_205, EINECS 204-040-1, Erythromycin A CRS, NSC 55929, 215031-94-0, Spectrum_000115, Spectrum_000659, AI3-50138, EM-A, Prestwick3_000151, Spectrum2_000759, Spectrum2_001263, Spectrum4_000538, Spectrum5_001596, UNII-8HPH7ND0LN, ERYTHROMYCIN [MI], GlyTouCan:G42935TE, E0751, ERYTHROMYCIN [INN], ERYTHROMYCIN [JAN], EC 204-040-1, ERYTHROMYCIN [HSDB], SCHEMBL2601, ERYTHROMYCIN [VANDF], BSPBio_000282, BSPBio_002480, ERYTHROMYCIN [MART.], KBioGR_001175, KBioSS_000555, KBioSS_001139, MLS001066618, BIDD:GT0017, DivK1c_000294, DivK1c_000397, DivK1c_000702, ERYTHROMYCIN [USP-RS], ERYTHROMYCIN [WHO-DD], ERYTHROMYCIN [WHO-IP], SPECTRUM1500280, SPBio_000778, SPBio_001226, Erythromycin (mixture A,B,C), BPBio1_000312, GTPL1456, orb1309999, orb3025580, Erythromycin (JP18/USP/INN), HMS500O16, KBio1_000294, KBio1_000397, KBio1_000702, KBio2_000555, KBio2_001139, KBio2_003123, KBio2_003707, KBio2_005691, KBio2_006275, ERYTHROMYCIN [GREEN BOOK], MSK7801, NINDS_000294, NINDS_000397, NINDS_000702, ERYTHROMYCIN [ORANGE BOOK], HMS1920M04, HMS2091D05, HMS2095O04, HMS3712O04, Pharmakon1600-01500280, ERYTHROMYCIN [EP MONOGRAPH], G42935TE, HY-B0220, RKL10096, ERYTHROMYCIN [USP MONOGRAPH], Tox21_111311, Tox21_111869, Tox21_300515, BDBM50344942, CCG-38992, LMPK04000006, MSK7801-100A, MSK7801-100M, NSC756759, ERYTHROMYCINUM [WHO-IP LATIN], AKOS015895249, MSK7801-1000A, MSK7801-1000M, AE22796, DB00199, Erythromycin for system suitability CRS, NSC-756759, BENZAMYCIN COMPONENT ERYTHROMYCIN, IDI1_000294, IDI1_000397, IDI1_000702, SMP1_000119, NCGC00179619-01, NCGC00179619-02, NCGC00179619-03, NCGC00254234-01, AC-12744, AC-12901, SMR000544946, SY070227, Erythromycin for microbiological assay CRS, Erythromycin, potency: >=850 mug per mg, Erythromycin, tested according to Ph.Eur., SBI-0051368.P003, Erythromycin, N-demethyl-N-(methyl-11C)-, Erythromycin 1000 microg/mL in Acetonitrile, Erythromycin Solution in Methanol, 100ug/mL, NS00000203, Third international Standard for Erythromycin, Erythromycin for impurity M identification CRS, Erythromycin Solution in Methanol, 1000ug/mL, Erythromycin, meets USP testing specifications, C01912, D00140, E-3250, AB00051981_09, AB00051981_10, Erythromycin Solution in Acetonitrile, 100ug/mL, Erythromycin, Biotechnology Performance Certified, Erythromycin estolate impurity, free erythromycin-, Erythromycin Solution in Acetonitrile, 1000ug/mL, Q213511, SR-01000799155, Erythromycin, Antibiotic for Culture Media Use Only, Erythromycin, BioReagent, suitable for cell culture, SR-01000799155-2, SR-05000001618-1, SR-05000001618-2, BRD-K63550407-001-12-7, BRD-K63550407-001-13-5, BRD-K63550407-028-03-9, BRD-K63550407-028-04-7, Z2587996953, Erythromycin A, European Pharmacopoeia (EP) Reference Standard, Roxithromycin EP Impurity A; Erythromycin;Erythromycin A(USP), Erythromycin, United States Pharmacopeia (USP) Reference Standard, ERYTHROMYCIN ESTOLATE IMPURITY, FREE ERYTHROMYCIN [EP IMPURITY], ERYTHROMYCIN ESTOLATE IMPURITY, FREE ERYTHROMYCIN- [USP IMPURITY], Erythromycin, for microbiological assay, European Pharmacopoeia (EP) Reference Standard, Erythromycin, Pharmaceutical Secondary Standard; Certified Reference Material, (3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-, (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyloxy)-14-ethyl-7,12,13-trihydroxy-6-[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyloxy]-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione, (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione (non-preferred name), [3R-(3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)]-4-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-|A-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-|A-D-xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione, Erythromycin A; Dotycin; Erycin; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-ethyl-7,12,13-trihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione
Theoretical properties:
molecular_formula: C37H67NO13
molecular_weight: 733.9 g/mol
exact_mass: 733.46124119 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 5
hydrogen_bond_acceptor_count: 14
rotatable_bond_count: 7
heavy_atom_count: 51
topological_polar_surface_area: 194 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
physical_state: Hydrated crystals from water
color: Hydrated crystals from water
odor: Odorless
melting_point: 133-135
solubility: Soluble in water at 2mg/ml
Descriptions:
{"pubchem": "Erythromycin A is an erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively. It is a cyclic ketone and an erythromycin. It is functionally related to an erythronolide A. It is a conjugate base of an erythromycin A(1+).", "chebi": "An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-<em>C</em>-methyl-3-<em>O</em>-methyl-\u03b1-<small>L</small>-<i>ribo</i>-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-\u03b2-<small>D</small>-<i>xylo</i>-hexopyranosyl residues attahced at positions 4 and 6 respectively.", "chembl": "ERYTHROMYCIN is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.", "wikipedia": "Erythromycin (sometimes abbreviated ETM in reports) is an antibiotic used for the treatment of a number of bacterial infections. This includes respiratory tract infections, skin infections, chlamydia infections, pelvic inflammatory disease, and syphilis. It may also be used during pregnancy to prevent Group B streptococcal infection in the newborn, and to improve delayed stomach emptying. It can be given intravenously and by mouth. An eye ointment is routinely recommended after delivery to prevent eye infections in the newborn.\nCommon side effects include abdominal cramps, vomiting, and diarrhea. More serious side effects may include Clostridioides difficile colitis, liver problems, prolonged QT, and allergic reactions. It is generally safe in those who are allergic to penicillin. Erythromycin also appears to be safe to use during pregnancy. While generally regarded as safe during breastfeeding, its use by the mother during the first two weeks of life may increase the risk of pyloric stenosis in the baby. This risk also applies if taken directly by the baby during this age. It is in the macrolide family of antibiotics and works by decreasing bacterial protein production.\nErythromycin was first isolated in 1952 from the bacteria Saccharopolyspora erythraea. It is on the World Health Organization's List of Essential Medicines. In 2023, it was the 235th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\n"}